NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets closed

Neurocrine Biosciences, Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
53.28-0.34 (-0.63%)
At close: 4:00PM EDT

53.28 0.00 (0.00%)
After hours: 4:55PM EDT

People also watch
ALKSPGNXLGNDNKTRINCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close53.62
Open51.95
Bid52.50 x 500
Ask0.00 x
Day's Range51.85 - 54.13
52 Week Range37.35 - 55.15
Volume3,140,844
Avg. Volume1,255,116
Market Cap4.64B
Beta1.76
PE Ratio (TTM)-32.69
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire2 hours ago

    Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering

    The notes will be sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Neurocrine also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $67.5 million aggregate principal amount of notes. The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable in cash semi-annually in arrears at a rate of 2.25% per annum.

  • MarketWatch3 hours ago

    Neurocrine Biosciences’ new drug may cost patients taking recommended dose twice as much as expected

    Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about ...

  • PR Newswireyesterday

    Neurocrine Announces Proposed Convertible Senior Notes Offering

    SAN DIEGO, April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable semiannually in arrears. The notes will be convertible in certain circumstances into cash, shares of Neurocrine's common stock, or a combination of cash and shares of Neurocrine's common stock, at Neurocrine's election.